121 related articles for article (PubMed ID: 30270111)
1. Letter comments on EJC published article: Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2-positive breast carcinomatous meningitis.
Hofer S; Aebi S
Eur J Cancer; 2018 Nov; 103():279-280. PubMed ID: 30270111
[No Abstract] [Full Text] [Related]
2. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis.
Bonneau C; Paintaud G; Trédan O; Dubot C; Desvignes C; Dieras V; Taillibert S; Tresca P; Turbiez I; Li J; Passot C; Mefti F; Mouret-Fourme E; Le Rhun E; Gutierrez M
Eur J Cancer; 2018 May; 95():75-84. PubMed ID: 29635147
[TBL] [Abstract][Full Text] [Related]
3. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
Boskovitz A; McLendon RE; Okamura T; Sampson JH; Bigner DD; Zalutsky MR
Nucl Med Biol; 2009 Aug; 36(6):659-69. PubMed ID: 19647172
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
Park WY; Kim HJ; Kim K; Bae SB; Lee N; Lee KT; Won JH; Park HS; Lee SC
Cancer Res Treat; 2016 Apr; 48(2):843-7. PubMed ID: 25761487
[TBL] [Abstract][Full Text] [Related]
5. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.
Oliveira M; Braga S; Passos-Coelho JL; Fonseca R; Oliveira J
Breast Cancer Res Treat; 2011 Jun; 127(3):841-4. PubMed ID: 21369716
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis.
Mego M; Sycova-Mila Z; Obertova J; Rajec J; Liskova S; Palacka P; Porsok S; Mardiak J
Breast; 2011 Oct; 20(5):478-80. PubMed ID: 21700455
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis.
Zagouri F; Sergentanis TN; Bartsch R; Berghoff AS; Chrysikos D; de Azambuja E; Dimopoulos MA; Preusser M
Breast Cancer Res Treat; 2013 May; 139(1):13-22. PubMed ID: 23588955
[TBL] [Abstract][Full Text] [Related]
8. [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].
Gutierrez M; Lyazidi S; Brasseur L; Cvitkovic F; Le Scodan R
Bull Cancer; 2011 Apr; 98(4):417-24. PubMed ID: 21540147
[TBL] [Abstract][Full Text] [Related]
9. [Trastuzumab's association with cerebral metastases and meningeal carcinomatosis in a patient with HER2-positive breast cancer].
Ayuga Loro F; Jiménez Caballero PE; Martínez Barbeito MB; Cruz Mora MA
Med Clin (Barc); 2009 Jul; 133(7):279-80. PubMed ID: 19615485
[No Abstract] [Full Text] [Related]
10. [Intrathecal methotrexate in breast cancer meningeal carcinomatosis - Experience with a new administration schedule].
Cochereau D; Da Costa S; Le Maignan C; Gauthier H; Cochereau J; Espié M; Giacchetti S; Teixeira L
Bull Cancer; 2016 May; 103(5):444-54. PubMed ID: 26987841
[TBL] [Abstract][Full Text] [Related]
11. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.
Stemmler HJ; Mengele K; Schmitt M; Harbeck N; Laessig D; Herrmann KA; Schaffer P; Heinemann V
Anticancer Drugs; 2008 Sep; 19(8):832-6. PubMed ID: 18690096
[TBL] [Abstract][Full Text] [Related]
12. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases.
Martens J; Venuturumilli P; Corbets L; Bestul D
Acta Oncol; 2013 Jan; 52(1):175-8. PubMed ID: 22655969
[No Abstract] [Full Text] [Related]
13. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis.
Perissinotti AJ; Reeves DJ
Ann Pharmacother; 2010 Oct; 44(10):1633-40. PubMed ID: 20807868
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience.
Figura NB; Long W; Yu M; Robinson TJ; Mokhtari S; Etame AB; Tran ND; Diaz R; Soliman H; Han HS; Sahebjam S; Forsyth PA; Ahmed KA
Breast Cancer Res Treat; 2018 Jun; 169(2):391-396. PubMed ID: 29392582
[TBL] [Abstract][Full Text] [Related]
15. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
[TBL] [Abstract][Full Text] [Related]
16. Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.
Lavaud P; Rousseau B; Ajgal Z; Arrondeau J; Huillard O; Alexandre J; Hulin A; Goldwasser F
Breast Cancer Res Treat; 2016 May; 157(1):191-2. PubMed ID: 27106482
[No Abstract] [Full Text] [Related]
17. Intrathecal trastuzumab: What else do we need to consider?
Gao T; Zhang S; Li M
Neuro Oncol; 2023 Feb; 25(2):418-419. PubMed ID: 36534954
[No Abstract] [Full Text] [Related]
18. The necessity of intrathecal chemotherapy for the treatment of breast cancer patients with leptomeningeal metastasis: A systematic review and pooled analysis.
Lee YC; Hsieh CC; Chuang JP; Li CY
Curr Probl Cancer; 2017; 41(5):355-370. PubMed ID: 28779849
[TBL] [Abstract][Full Text] [Related]
19. [A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy].
Takahashi H; Fujii T; Inoue Y; Katsura M; Yokoyama G; Matsubayashi Namoto R; Nakayama Y; Momosaki S; Ariyama H; Takenaka M; Otsuka H; Iwakuma N; Toh U; Shirouzu K
Gan To Kagaku Ryoho; 2010 Aug; 37(8):1607-9. PubMed ID: 20716898
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
